Compass plots quicker path to approval, launch readiness for depression drugnews2025-11-04T11:46:13+00:00November 4th, 2025|Endpoints News|
Nuvation Bio backs off from head-to-head brain cancer trialnews2025-11-04T10:33:54+00:00November 4th, 2025|Endpoints News|
Duchenne confirmatory trial fails, but Sarepta to ask FDA for full approval anywaysnews2025-11-04T00:20:06+00:00November 4th, 2025|Endpoints News|
Day after resigning, Tidmarsh now says he’ll fight exit from FDAnews2025-11-03T20:55:14+00:00November 3rd, 2025|Endpoints News|
AbbVie gets early win in Oklahoma 340B fight, but faces setback in Coloradonews2025-11-03T20:18:49+00:00November 3rd, 2025|Endpoints News|
Lilly earmarks $3B for new European obesity pill factory news2025-11-03T17:58:52+00:00November 3rd, 2025|Endpoints News|
UK regulators look to speed up how rare disease therapies reach the marketnews2025-11-03T17:24:47+00:00November 3rd, 2025|Endpoints News|
Metsera calls Pfizer threats ‘nonsense’ as rift widens between companiesnews2025-11-03T16:46:46+00:00November 3rd, 2025|Endpoints News|
TScan to cut a third of its staff; Iovance advances Amtagvi in lung cancernews2025-11-03T15:43:34+00:00November 3rd, 2025|Endpoints News|
#ASH25: Lilly’s Jaypirca matches Imbruvica in Phase 3 early blood cancer trialnews2025-11-03T14:00:27+00:00November 3rd, 2025|Endpoints News|
